Day One Biopharmaceuticals Inc [NASDAQ: DAWN] price plunged by -9.87 percent to reach at -$0.69.
The one-year DAWN stock forecast points to a potential upside of 77.99. The average equity rating for DAWN stock is currently 1.22, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Day One Biopharmaceuticals Inc [DAWN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DAWN shares is $28.62 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DAWN stock is a recommendation set at 1.22. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Needham have made an estimate for Day One Biopharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 09, 2024. While these analysts kept the previous recommendation, BofA Securities raised their target price from $11 to $24. The new note on the price target was released on August 01, 2024, representing the official price target for Day One Biopharmaceuticals Inc stock. Previously, the target price had yet another raise from $30 to $33, while Needham kept a Buy rating on DAWN stock. On April 25, 2023, analysts decreased their price target for DAWN shares from 34 to 9.
The Average True Range (ATR) for Day One Biopharmaceuticals Inc is set at 0.53, with the Price to Sales ratio for DAWN stock in the period of the last 12 months amounting to 3.94. The Price to Book ratio for the last quarter was 1.33, with the Price to Cash per share for the same quarter was set at 4.67.
DAWN Stock Performance Analysis:
Day One Biopharmaceuticals Inc [DAWN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -19.02. With this latest performance, DAWN shares dropped by -10.26% in over the last four-week period, additionally sinking by -57.00% over the last 6 months – not to mention a drop of -63.31% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DAWN stock in for the last two-week period is set at 33.26, with the RSI for the last a single of trading hit 28.19, and the three-weeks RSI is set at 35.42 for Day One Biopharmaceuticals Inc [DAWN]. The present Moving Average for the last 50 days of trading for this stock 7.92, while it was recorded at 7.26 for the last single week of trading, and 12.17 for the last 200 days.
Insight into Day One Biopharmaceuticals Inc Fundamentals:
Day One Biopharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.55 and a Current Ratio set at 10.62.
Day One Biopharmaceuticals Inc [DAWN] Institutonal Ownership Details
The top three institutional holders of DAWN stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 7.87 million shares, which is approximately 9.0354%. ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, holding 6.43 million shares of the stock with an approximate value of $$88.61 million in DAWN stocks shares; and ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, currently with $$63.71 million in DAWN stock with ownership which is approximately 5.3067%.
